Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Epinastine + Pseudoephedrine vs Epinastine in Perennial Allergic Rhinitis
NCT02182518Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2000
- Primary completion
- Jul 2001
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of epinastine, pseudoephedrine in perennial allergic rhinitis (PAR), sponsored by Boehringer Ingelheim. Started May 2000; status: completed.
02
Drugs
epinastinepseudoephedrine
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT02182518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182518.